Wednesday, June 10, 2026

Patent intelligence · US

US 11795130

Process for separating a constituent/cannabinoid using a chromatographic resin

granted A61KA61K31/05A61K31/192A61K31/352
Status granted
Linked drugs 3
Pipeline programs 6
Years to expiry 17
Applicant portfolio 308
Patent details — US 11795130
Jurisdiction
US
Status
granted
Grant date
Oct 24, 2023
Expiration
Oct 19, 2043
Applicant
KAZMIRA LLC.
Claims
40
CPC classes
A61K, A61K31/05, A61K31/192, A61K31/352
View on Google Patents ↗

Quick answer

US 11795130 (Process for separating a constituent/cannabinoid using a chromatographic resin) is held by KAZMIRA LLC.. Status: granted. Granted Oct 24, 2023. Expires Oct 19, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Applicant
KAZMIRA LLC.
Grant date
Expiration
Claims
40
CPC classes
A61K, A61K31/05, A61K31/192, A61K31/352, A61K31/658

More from KAZMIRA LLC.

Related pharmaceutical patents in our USPTO index.

  1. US 12421228

    Naphthyridine derivatives as PRC2 inhibitors

    Mirati Therapeutics, Inc. · Expires Sep 18, 2045

    granted
  2. US 12421253

    Tetrahydropyridopyrimidine pan-KRas inhibitors

    Mirati Therapeutics, Inc. · Expires Sep 18, 2045

    granted
  3. US 12414911

    Topical compositions and methods of use

    MIRACLE FRUIT OIL L.L.C. · Expires Sep 11, 2045

    granted
  4. US 12412764

    Substrate-accommodating container

    MIRAIAL CO., LTD. · Expires Sep 4, 2045

    granted
  5. US 12398154

    Azaquinazoline pan-KRas inhibitors

    Mirati Therapeutics, Inc. · Expires Aug 21, 2045

    granted
  6. US 12383503

    Adagrasib solid pharmaceutical compositions

    Mirati Therapeutics, Inc. · Expires Aug 7, 2045

    granted
  7. US 12377101

    Combination therapies

    Mirati Therapeutics, Inc. · Expires Jul 31, 2045

    granted
  8. US 12371435

    Substituted imidazo[1,2-c]pyrimidines as PRC2 inhibitors

    Mirati Therapeutics, Inc. · Expires Jul 24, 2045

    granted

Frequently asked questions

What is US patent 11795130?

US 11795130 (Process for separating a constituent/cannabinoid using a chromatographic resin) is held by KAZMIRA LLC.. Status: granted. Granted Oct 24, 2023. Expires Oct 19, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 11795130?

KAZMIRA LLC. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 308 pharmaceutical patents for this assignee.

When does US 11795130 expire?

Our index shows an expiration date of Oct 19, 2043 (17 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.